ライフサイエンスコーパス: Cannabis

1 destructive differentiation between hemp and cannabis.

2 uivalent cannabis, and 18.28 cm with placebo cannabis.

3 tions, particularly those who frequently use cannabis.

4 al use have regulated production and sale of cannabis.

5 uivalent cannabis, and 19.37 cm with placebo cannabis.

6 procedure to provide evidence of exposure to cannabis.

7 ating the appetite stimulating properties of cannabis.

8 high risk group that used high quantities of cannabis.

9 and consumption of recreational and medical cannabis.

10 ts (N = 26) were healthy occasional users of cannabis.

11 BD-dominant, THC/CBD-equivalent, and placebo cannabis.

12 ogy to unravel the complex phytochemistry of cannabis.

13 .28 to 4.39]; P < .001) but not CBD-dominant cannabis (-0.05 cm [95% CI, -1.49 to 1.39]; P > .99), re

14 ion, the SDLP was 19.03 cm with CBD-dominant cannabis, 19.88 cm with THC-dominant cannabis, 20.59 cm

15 was significantly increased by THC-dominant cannabis (+2.33 cm [95% CI, 0.80 to 3.86]; P < .001) and

16 0 to 3.86]; P < .001) and THC/CBD-equivalent cannabis (+2.83 cm [95% CI, 1.28 to 4.39]; P < .001) but

17 ion, the SDLP was 18.21 cm with CBD-dominant cannabis, 20.59 cm with THC-dominant cannabis, 21.09 cm

18 ominant cannabis, 19.88 cm with THC-dominant cannabis, 20.59 cm with THC/CBD-equivalent cannabis, and

19 ominant cannabis, 20.59 cm with THC-dominant cannabis, 21.09 cm with THC/CBD-equivalent cannabis, and

20 odds for daily use of high-potency types of cannabis (4.8, 2.5-6.3).

21 ad used tobacco (55.5%), alcohol (66.9%), or cannabis (49.9%) in the past month.

22 ultaneous quantification of 93 terpenoids in Cannabis air-dried inflorescences and extracts.

23 ill be valuable for interrogating effects of cannabis and delineating neural mechanisms that give ris

24 rature review on the evolutionary history of Cannabis and Humulus, including medicinal and industrial

25 nol (THC) is the intoxicating constituent of cannabis and is responsible for the drug's reinforcing e

26 Cannabis and its derivatives affect many gastrointestina

27 We review the ECS and the effects of cannabis and its derivatives on gastrointestinal and hep

28 With the growing global acceptance of cannabis and its widespread use by eyewitnesses and susp

29 cumulating evidence suggests that the use of cannabis and nicotine and tobacco-related products (NTPs

30 Consistent with the literature, cannabis and nicotine were found to have independent eff

31 is warranted to investigate the influence of cannabis and NTP co-use on maturation.

32 tional neuroimaging outcomes associated with cannabis and NTP co-use.

33 r preclinical studies, nonadult subjects; 3) cannabis and NTP group jointly considered; and 4) neuroc

34 The available research on the co-use of cannabis and NTPs demonstrates a potential nicotine-rela

35 in as it relates to the co-administration of cannabis and NTPs, despite the high prevalence rates of

36 The use of cannabis and other exocannabinoids as anecdotal treatmen

37 significant differences between CBD-dominant cannabis and placebo.

38 ers an ideal tool for terpenoid profiling of Cannabis and sets the scene for more comprehensive works

39 ers, we test the association between various cannabis and spliff use behaviours and likeliness to smo

40 The decriminalization and legalization of cannabis and the expansion of availability of medical ca

41 ere has been minimal research around various cannabis and tobacco mixing (spliff usage) behaviours an

42 t cannabis, 21.09 cm with THC/CBD-equivalent cannabis, and 18.28 cm with placebo cannabis.

43 t cannabis, 20.59 cm with THC/CBD-equivalent cannabis, and 19.37 cm with placebo cannabis.

44 e confirmatory differentiation between hemp, cannabis, and CBD-rich hemp.

45 noid receptors, which mediate the actions of cannabis, are abundantly expressed in brain regions know

46 ited States by the ongoing classification of cannabis as a Schedule 1 controlled substance.

47 Edible products accounted for 10.7% of cannabis-attributable visits between 2014 and 2016 but r

48 ts, undesired or even detrimental effects of cannabis can limit its use.

49 Cannabis (Cannabis sativa) resin is the foundation of a

50 9-THC), the major psychoactive ingredient in cannabis, causes fetal growth restriction, though the me

51 that RS can be used to differentiate between cannabis, CBD-rich plants, and regular hemp.

52 Three medical Cannabis chemovars were used to study the effect of samp

53 reported and used for metabolic analysis of Cannabis chemovars.

54 aporized THC-dominant and THC/CBD-equivalent cannabis compared with placebo was significantly greater

55 The detection of cannabis constituents and metabolites in hair is an esta

56 ctions of synthetic cannabinoids or isolated cannabis constituents that may not capture the complex e

57 ommenced at 40 minutes and 240 minutes after cannabis consumption.

58 ot capture the complex effects of volitional cannabis consumption.

59 Although Cannabis contains an overwhelming milieu of terpenoids,

60 natal, perinatal, and adolescent exposure to cannabis/delta-9-tetrahydrocannabinol.

61 sity differences between 89 individuals with cannabis dependence (CD) and 89 matched controls (64 mal

62 o tobacco smokers are more likely to exhibit cannabis dependence and psychosocial problems.

63 ll, and increased reports of the severity of cannabis dependence.

64 Medical use of cannabis derivatives is a current hot topic and it is un

65 f CBD that is prepared from inexpensive, non-cannabis derived precursors.

66 rocannabinol, the psychoactive ingredient of cannabis, disrupts autophagy selectively in the striatum

67 es have seen a revolution in legal access to cannabis, driven largely by activists and business inter

68 growth restriction observed in women who use cannabis during pregnancy.

69 No cannabis effect was observed on cellular HIV RNA transcr

70 identify, understand and potentially reduce cannabis-evoked harms are warranted.

71 roducts were detected from both pure THC and cannabis experiments, with the product ratios dependent

72 Prenatal cannabis exposure (PCE) influences human brain developme

73 s (r = -0.55; P = 0.026) and higher previous cannabis exposure (r = 0.52; P = 0.040) were associated

74 lative risk (RR) of outcomes associated with cannabis exposure and control for confounding.

75 ons regarding accurate modeling of perinatal cannabis exposure as well as the need for sex- and age-d

76 Self-reported cannabis exposure in pregnancy was ascertained through r

77 valence of detrimental outcomes of perinatal cannabis exposure is likely to increase in tandem with t

78 ledge on the potential effects of adolescent cannabis exposure on brain development and identify pote

79 the immediate and protracted consequences of cannabis exposure on pre- and postnatal development.

80 These results were not explained by past cannabis exposure or current intake of antipsychotic med

81 We found that vapor cannabis exposure promoted food intake in free-feeding a

82 participants (7 males) with modest previous cannabis exposure.

83 ng response-contingent delivery of vaporized cannabis extracts containing high concentrations of Delt

84 ) or cannabidiol-rich (CAN(CBD)) whole-plant cannabis extracts.

85 The long history of individual use of cannabis for a wide range of conditions has sparked grea

86 s the potential to provide enhanced forms of Cannabis for biopharmaceutical manufacture.

87 is increasing as more states are legalizing cannabis for both medicinal and recreational purposes.

88 eviews the use of medicinal and recreational cannabis from a clinical but also a policy and public he

89 We demonstrate that current Cannabis genome assemblies are incomplete, with ~10% mis

90 from two sets of botanical extracts from the Cannabis genus.

91 a diversity panel derived from the Ecofibre Cannabis germplasm collection, an extreme-phenotype geno

92 alues of structural neuroimaging measures by cannabis group were similar across regions, and any diff

93 us has limited its availability in research; cannabis has been legalized only recently, in some state

94 understanding of the safety and efficacy of cannabis has been limited by decades of worldwide illega

95 Medical cannabis has been touted as a solution to the US opioid

96 ceived risk by youth associated with smoking cannabis has declined in recent years.

97 ndocannabinoid system, the primary target of cannabis, has been implicated in psychosis.

98 disease and the anti-inflammatory effects of cannabis have been investigated in patients with inflamm

99 Over the past 25 years, attitudes toward cannabis have evolved rapidly, with expanding legalizati

100 examine the combined effects of nicotine and cannabis in adolescent-only populations.

101 and the expansion of availability of medical cannabis in North America have led to an increase in can

102 Because of increasing access to and use of cannabis in the general population, along with a high pr

103 mg/2 ml), the key psychoactive ingredient in cannabis, in a set of 16 healthy participants (7 males)

104 any of the concerning health implications of cannabis include cardiovascular diseases, although they

105 striatal glutamate levels may underlie acute cannabis-induced psychosis while lower baseline levels m

106 A major problem in the cannabis industry is the lack of proper metabolic charac

107 rising from the legalisation of a commercial cannabis industry.

108 r optimized SBSE conditions, eight different cannabis inflorescences and a quality control sample wer

109 Specifically, cannabis inflorescences were considered and stir bar sor

110 for the preclinical assessment of volitional cannabis intake and cannabis-seeking behaviors.SIGNIFICA

111 urrent study investigated the association of cannabis involvement with WM performance and associated

112 The use of high-potency cannabis is associated with cannabis use disorder and in

113 s particularly timely as the legal status of cannabis is changing in many jurisdictions and the perce

114 Cannabis is one of the most commonly and widely used psy

115 The use of cannabis is rapidly expanding worldwide.

116 d, but the association between state medical cannabis laws and opioid overdose mortality reversed dir

117 d that from 1999 to 2010 states with medical cannabis laws experienced slower increases in opioid ana

118 more restrictive (low-tetrahydrocannabinol) cannabis laws were associated with changes in opioid ove

119 ontinue, but the claim that enacting medical cannabis laws will reduce opioid overdose death should b

120 d positive after accounting for recreational cannabis laws.

121 CANCE STATEMENT With the increasing trend of cannabis legalization and consumption during adolescence

122 Recent trends in cannabis legalization have increased the necessity to be

123 drolase (FAAH, C385A), which metabolizes the cannabis-like endocannabinoid anandamide, and dopaminerg

124 for policy and prevention measures as legal cannabis markets continue to emerge worldwide.

125 stand findings, important given expanding US cannabis markets.

126 ontrast, pre-clinical research suggests that cannabis may affect dopamine via modulation of glutamate

127 Cannabis may have therapeutic benefits, but few are card

128 However, the effect size for CBD-dominant cannabis may not have excluded clinically important impa

129 the internet related to glaucoma and medical cannabis (MC).

130 The rates of cannabis misuse have been increasing.

131 t for causal and graded liability effects of cannabis on precuneus structure.

132 le empirical support for an effect of THC or cannabis on working memory.

133 It is widely believed that cannabis, or its main psychoactive component Delta(9)-te

134 Cannabis, or marijuana, has potential therapeutic and me

135 tic cannabinoids or active components of the cannabis plant), in addition to significant alterations

136 CBD may be sourced from cannabis plants but can also be prepared synthetically,

137 fferent cannabinoids have been isolated from Cannabis plants, clear physiological effects of only a f

138 the non-psychoactive compound isolated from cannabis plants, was recently approved for treatment of

139 Cannabis potency is determined by the concentration of D

140 Cannabis produces a class of isoprenylated resorcinyl po

141 public health impacts of the legalisation of cannabis production, sale, and use in the Americas.

142 Men consume the most nicotine and cannabis products but impacts on sperm epigenetics are p

143 ew, we highlight the influence that changing cannabis products have on adolescent health and the impl

144 As a result, the consumption of cannabis products is increasing considerably, particular

145 t the relative harms of edible and inhalable cannabis products.

146 Furthermore, both cannabis regimens produced ecologically relevant brain c

147 rapidly changing legal and medical status of cannabis-related compounds, makes understanding how exog

148 s, morning users reported significantly more cannabis-related problems.

149 C, two biomarkers previously associated with cannabis-related psychiatric risk and subcortical DAergi

150 Major components of the cannabis resin are the cannabinoids and terpenes.

151 and 2016 but represented only 0.32% of total cannabis sales in Colorado (in kilograms of tetrahydroca

152 The capitate-stalked glandular trichomes of Cannabis sativa (cannabis), situated on the surfaces of

153 Cannabis sativa alters sensory perception and exhibits p

154 Cannabis sativa and its principal components, Delta9-tet

155 Cannabis sativa is widely cultivated for medicinal, food

156 Cannabis sativa L. has been cultivated and used around t

157 Cannabis sativa L. is a multi-purpose crop, traditionall

158 Cannabis sativa L. is a valuable plant that has regained

159 Cannabis sativa L. is an important yet controversial pla

160 Here we explore the potential of hemp (Cannabis sativa L.) for these phytotechnologies.

161 Industrial hemp (Cannabis sativa L.) is a high-yielding annual crop prima

162 set includes samples from hemp, a variety of Cannabis sativa with the THC concentration below 0.3%.

163 Hemp (Cannabis sativa) has been used to treat pain as far back

164 Cannabis (Cannabis sativa) resin is the foundation of a multibilli

165 Cannabis sativa, also known as marijuana or hemp, produc

166 Cannabis' schedule 1 drug status has limited its availab

167 inction burst and an increase in cue-induced cannabis-seeking behavior relative to VEH.

168 neural mechanisms that give rise to aberrant cannabis-seeking behavior.

169 assessment of volitional cannabis intake and cannabis-seeking behaviors.SIGNIFICANCE STATEMENT The ev

170 Cannabis seems to increase false-memory proneness, with

171 e field, we have developed a novel method of cannabis self-administration using response-contingent d

172 We have developed a novel model of cannabis self-administration using response-contingent d

173 Research into therapeutic potential of cannabis should continue, but the claim that enacting me

174 lked glandular trichomes of Cannabis sativa (cannabis), situated on the surfaces of the bracts of the

175 uggest that their contributions to thirdhand cannabis smoke will be less significant than the role th

176 ahydrocannabinol (THC), a major component of cannabis smoke, with ozone was examined as a pure compou

177 e was examined as a pure compound and within cannabis smoke.

178 logeny of the CsTPS gene family showed three cannabis-specific clades, including a clade of sesquiter

179 Here, we tested the hypothesis that cannabis targets alternative polyadenylation (APA) sites

180 Variations of cannabis terpene profiles contribute much to the differe

181 Purple Kush revealed a total of 33 different cannabis terpene synthase (CsTPS) genes, as well as vari

182 that collectively explain a diverse range of cannabis terpenes.

183 isorder is characterised by recurrent use of cannabis that causes significant clinical and functional

184 the increasing availability of high-potency cannabis, this has important implications for public hea

185 Cannabis THS is a chemically distinct and prevalent form

186 Cannabis usage is increasing with its widespread legaliz

187 atio [OR] 2.78, 95% CI 1.35-5.74; p=0.0059), cannabis use (2.61, 1.11-6.14; p=0.029), other illicit d

188 ease abstinence rates (moderate SOE), reduce cannabis use (low SOE), or increase treatment retention

189 ies (GWAS) of ADHD (n = 53,293) and lifetime cannabis use (n = 32,330) to gain insights into the gene

190 m at baseline, the strongest predictors were cannabis use (OR 2.14, 95% CI 1.04-4.41; p=0.038), other

191 derlie the association, direct evidence that cannabis use affects either acute or chronic striatal do

192 Rates of cannabis use among adolescents are high, and are increas

193 lysis was to investigate the extent to which cannabis use among youths is associated with the risk of

194 tion was 6.1% among women who did not report cannabis use and 12.0% among those reporting use in the

195 echanisms underlying the association between cannabis use and acute or long-lasting psychosis are not

196 With the increasing prevalence of legal cannabis use and availability, there is an urgent need t

197 differences in the prevalence of nonmedical cannabis use and cannabis use disorder among U.S. adults

198 be an emerging group at risk for nonmedical cannabis use and cannabis use disorder.

199 d females) with just one or two instances of cannabis use and carefully matched THC-naive controls.

200 six participants, stratified by severity of cannabis use and desire to quit.

201 endent negative association between frequent cannabis use and frequent illicit opioid use among PWUD

202 ongitudinal association between frequency of cannabis use and illicit opioid use among people who use

203 s demonstrate a moderate association between cannabis use and physical violence, which remained signi

204 emporal relationship between ADHD and future cannabis use and reinforce the need to consider substanc

205 in North America have led to an increase in cannabis use and the availability of high-potency strain

206 All studies that examined both cannabis use and the perpetration of physical violence i

207 ADHD and cannabis use are partly determined by genetic factors; t

208 Finally, we discuss cannabis use as a factor that may have a unique impact d

209 butable fractions (PAFs) for the patterns of cannabis use associated with the highest odds of psychos

210 Cannabis use by mothers during lactation transfers activ

211 Cannabis use by risk group interactions were observed in

212 concurrent and lasting effects of adolescent cannabis use can be observed on important cognitive func

213 ls to the data to estimate which patterns of cannabis use carried the highest odds for psychotic diso

214 The prevalence of frequent nonmedical cannabis use did not differ by pain status in the 2001-2

215 equal number (n = 12) of subjects with DSM-5 cannabis use disorder (CUD) and matched healthy controls

216 Cannabis use disorder (CUD) is a growing concern, and ev

217 lthy controls and thirteen participants with cannabis use disorder (CUD) twice after placebo and afte

218 he prevalence of nonmedical cannabis use and cannabis use disorder among U.S. adults with and without

219 of high-potency cannabis is associated with cannabis use disorder and increased susceptibility to ps

220 s in the United States now meet criteria for cannabis use disorder annually.

221 also reviewing the developmental pathways of cannabis use disorder as well as evidence-based pharmaco

222 l pathological consequences of cannabis use, cannabis use disorder is a clinical diagnosis with high

223 Cannabis use disorder is characterised by recurrent use

224 Cannabis use disorder was more prevalent in respondents

225 ree times a week) nonmedical use, and DSM-IV cannabis use disorder were estimated for groups with and

226 ding neurobiological systems associated with cannabis use disorder, which often share common neural c

227 nce of lower hippocampal synaptic density in cannabis use disorder.

228 itor such patients for signs and symptoms of cannabis use disorder.

229 roup at risk for nonmedical cannabis use and cannabis use disorder.

230 (F10.X-19.X), alcohol use disorders (F10.X), cannabis use disorders (F12.X), and polydrug use disorde

231 Frequent cannabis use during adolescence has been associated with

232 Retrospective human studies suggest that cannabis use during adolescence is linked to long-term n

233 cit opioid use, and 410 (36%) reported daily cannabis use during at least one 6-month follow-up perio

234 Recent evidence suggests that cannabis use during pregnancy is increasing, although po

235 1 in 5 women report cannabis use during pregnancy, with nausea cited as thei

236 Cannabis use has been associated with increased crash ri

237 Medical and recreational cannabis use has increased dramatically over the last de

238 ving legal landscape concerning recreational cannabis use has increased urgency to better understand

239 Cannabis use histories varied markedly and participants

240 maturation during adolescence, a period when cannabis use in humans has been linked to subsequent vul

241 cannabis use, with an odds ratio of 7.9 for cannabis use in individuals with ADHD in comparison to i

242 7845 in reduction of cannabis withdrawal and cannabis use in men who were daily cannabis users.

243 uction in illicit drug use at 38 months (eg, cannabis use in the previous month, 10.7% in the interve

244 Cannabis use in this population is a risk factor for vio

245 When these high risk, high cannabis use individuals were compared to all other part

246 bility of ADHD is estimated at 70-80% and of cannabis use initiation at 40-48%.

247 In sum, chronic cannabis use is associated with structural differences i

248 Cannabis use is frequent among people living with human

249 Cannabis use is rising, yet there is poor understanding

250 Recreational cannabis use is understudied, especially in the adolesce

251 be more vulnerable to the effects of chronic cannabis use on cortical thickness.

252 Therefore, understanding the effects of cannabis use on the brain is important.

253 in reuptake inhibitors (SSRIs) do not reduce cannabis use or improve treatment retention.

254 e a group increasingly vulnerable to adverse cannabis use outcomes, warranting clinical and public he

255 It is well established that cannabis use promotes appetite.

256 These shifts in cannabis use require clinicians to understand conflictin

257 biological processes that might link chronic cannabis use to brain structural abnormalities.

258 95% CI 1.02 to 1.07, q = 0.008) for lifetime cannabis use to OR = 1.20 (95% CI 1.16 to 1.23, q = 1.33

259 Daily cannabis use was associated with increased odds of psych

260 Any nonmedical cannabis use was more prevalent in respondents with than

261 pregnant women in Ontario, Canada, reported cannabis use was significantly associated with an increa

262 We aimed to identify patterns of cannabis use with the strongest effect on odds of psycho

263 a, alcohol dependence disorder, and lifetime cannabis use) predicted self-harm, with effect sizes ran

264 Cannabis use, but not alcohol consumption, showed lagged

265 rding potential pathological consequences of cannabis use, cannabis use disorder is a clinical diagno

266 Risk differences of past-year nonmedical cannabis use, frequent (at least three times a week) non

267 nd very little about the earliest effects of cannabis use, however, because most research is conducte

268 This article focuses on the effects of cannabis use, intoxication, and withdrawal while also re

269 ower changes, head movement, antipsychotics, cannabis use, or IQ, and is not found in other frequency

270 d with discontinuation included younger age, cannabis use, STI, and fewer sex partners.

271 und support that ADHD is causal for lifetime cannabis use, with an odds ratio of 7.9 for cannabis use

272 effect on cognitive deficits associated with cannabis use, yet there is little research on co-use and

273 ecessity to better understand the effects of cannabis use.

274 ociated with the intersection of tobacco and cannabis use.

275 chiatric dysfunction that is associated with cannabis use.

276 cit drugs were used; any illicit drug or any cannabis use.

277 We find it unlikely that medical cannabis-used by about 2.5% of the US population-has exe

278 ely similar among adolescent and young adult cannabis users and non-users.

279 demographic characteristics between reported cannabis users and nonusers was attenuated using matchin

280 The number of cannabis users increased up to 188 million users worldwi

281 As a result, the population of cannabis users nationwide-especially daily users-has gro

282 Cannabis users who are also tobacco smokers are more lik

283 with a high prevalence of CUD among current cannabis users, an urgent need exists for more research

284 NA decay during antiretroviral therapy among cannabis users, compared to those with no drug use.

285 Whether similar alterations exist in human cannabis users, has not yet been demonstrated in vivo.

286 Compared to non-morning cannabis users, morning users reported significantly mor

287 Through a survey of US cannabis users, we test the association between various

288 ke that are consistent with effects in human cannabis users.

289 in corticolimbic and NAc properties in human cannabis users.

290 rawal and cannabis use in men who were daily cannabis users.

291 strated that surfaces exposed to side-stream cannabis vapor are positive for THC at quantifiable leve

292 first step in understanding how side-stream cannabis vapor deposits in the environment and potential

293 ndicate that volitional exposure to THC-rich cannabis vapor has bona fide reinforcing properties and

294 Our data indicate that THC-rich cannabis vapor has reinforcing properties that support s

295 Cannabis vapor reinforcement resulted in strong discrimi

296 ubstantial efforts have been made to develop Cannabis varieties that would produce large amounts of C

297 vs. 8.4%), and visits attributable to edible cannabis were more likely to be due to acute psychiatric

298 Visits attributable to inhaled cannabis were more likely to be for cannabinoid hypereme

299 and experimental evidence demonstrates that cannabis with high THC concentrations and negligible can

300 e FAAH-inhibitor PF-04457845 in reduction of cannabis withdrawal and cannabis use in men who were dai